Cargando…

Circulating Metabolic Markers Related to the Diagnosis of Hepatocellular Carcinoma

Primary liver carcinoma is the sixth most common cancer worldwide, while hepatocellular carcinoma (HCC) is the most dominant cancer type. Chronic hepatitis B and C virus infections and aflatoxin exposure are the main risk factors, while nonalcoholic fatty liver disease caused by obesity, diabetes, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Da, Zhang, Guangcong, Ma, Yanan, Wu, Dongyu, Jiang, Shuang, Zhou, Songke, Jiang, Xuemei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757943/ https://www.ncbi.nlm.nih.gov/pubmed/36532884 http://dx.doi.org/10.1155/2022/7840606

Ejemplares similares

Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma
por: Wu, Dongyu, et al.
Publicado: (2021)

Cell-free DNA methylation markers for differential diagnosis of hepatocellular carcinoma
por: Luo, Biyuan, et al.
Publicado: (2022)

Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular Carcinoma
por: Dhayat, Sameer A., et al.
Publicado: (2015)

Circulating MicroRNA Panel as a Diagnostic Marker for Hepatocellular Carcinoma
por: Wu, Xiaochang, et al.
Publicado: (2022)

Nomogram based on inflammation-related markers for predicting survival of patients undergoing hepatectomy for hepatocellular carcinoma
por: Pu, Tian, et al.
Publicado: (2021)

Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma
por: Luo, Jie, et al.
Publicado: (2013)

Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma
por: Yu, Jing, et al.
Publicado: (2021)

NLRC5, a valuable marker for the diagnosis and prognostic assessment of hepatocellular carcinoma
por: Zhang, Xiu-Wen, et al.
Publicado: (2020)

Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring
por: Wang, Li, et al.
Publicado: (2013)

The Potential Role of Circulating Long Miscellaneous RNAs in the Diagnosis and Prognosis of Hepatitis C Related Hepatocellular Carcinoma
por: Abdelsattar, Shimaa, et al.
Publicado: (2023)

Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR
por: Wang, Juan, et al.
Publicado: (2021)

Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
por: Zong, Jingjing, et al.
Publicado: (2020)

Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma
por: Li, Shuang, et al.
Publicado: (2022)

Association of circulating 25-Hydroxyvitamin D and its related genetic variations with hepatocellular carcinoma incidence and survival
por: Liu, Hui, et al.
Publicado: (2020)

Identification of MCM4 as a Prognostic Marker of Hepatocellular Carcinoma
por: Zhou, Huandi, et al.
Publicado: (2021)

The heterogeneity of plasma miRNA profiles in hepatocellular carcinoma patients and the exploration of diagnostic circulating miRNAs for hepatocellular carcinoma
por: Bai, Xue, et al.
Publicado: (2019)

Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma
por: Tokuhisa, Y, et al.
Publicado: (2007)

Methylation of S100A8 is a promising diagnosis and prognostic marker in hepatocellular carcinoma
por: Liu, Kun, et al.
Publicado: (2016)

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis
por: Zhao, Xiao-Fei, et al.
Publicado: (2020)

Research progress of circulating non-coding RNA in diagnosis and treatment of hepatocellular carcinoma
por: You, Junqi, et al.
Publicado: (2023)

The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
por: Pezzuto, Francesca, et al.
Publicado: (2018)

Hyperlactemia associated with secondary hepatocellular carcinoma resection in relation to circulation stability and quality of recovery: A case report
por: Meng, Yu, et al.
Publicado: (2023)

Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
por: Petrizzo, A., et al.
Publicado: (2018)

Development and Validation of Epigenetic Modification-Related Signals for the Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Lu, Maoqing, et al.
Publicado: (2021)

Characterization of metabolic landscape in hepatocellular carcinoma
por: Wu, Jing, et al.
Publicado: (2021)

Circulating tumor DNA in hepatocellular carcinoma: trends and challenges
por: Tang, Jia-Cheng, et al.
Publicado: (2016)

Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma.
por: Tsai, J. F., et al.
Publicado: (1995)

A Circulating Long Noncoding RNA Panel Serves as a Diagnostic Marker for Hepatocellular Carcinoma
por: Huang, Jinlan, et al.
Publicado: (2020)

The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Papatheodoridi, Alkistis, et al.
Publicado: (2021)

Atypical magnetic resonance imaging features and differential diagnosis of hepatocellular carcinoma
por: Wang, Shuang-Yu, et al.
Publicado: (2020)

Research progress on circulating tumor cells of hepatocellular carcinoma
por: Wan, Chenyu, et al.
Publicado: (2021)

Clinicopathological Features of Hepatocellular Carcinoma with Metabolic Risk Factors
por: Sun, Lei, et al.
Publicado: (2023)

Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma
por: Mansour, Lamiaa A, et al.
Publicado: (2017)

Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma
por: Xie, Xuancheng, et al.
Publicado: (2022)

Effects of Cirrhosis and Diagnosis Scenario in Metabolic‐Associated Fatty Liver Disease‐Related Hepatocellular Carcinoma
por: Chen, Vincent L., et al.
Publicado: (2020)

A metabolism-related gene signature for predicting the prognosis and therapeutic responses in patients with hepatocellular carcinoma
por: Dai, Xiaoyan, et al.
Publicado: (2021)

Epithelial–mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease
por: Li, Y-M, et al.
Publicado: (2013)

Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma
por: Huang, Ao, et al.
Publicado: (2016)

Tumor markers for hepatocellular carcinoma
por: ZHAO, YAN-JIE, et al.
Publicado: (2013)

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma
por: Liu, Fangming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2nm5ff35reebpj6vb5mqe1df6f